Brief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
08/10/2026 23:20
BRIEF-Guardant Health Announces Approval In Europe Of Guardant360® Cdx Oct 8 (Reuters) - Guardant Health, Inc. GH.O:
GUARDANT HEALTH ANNOUNCES APPROVAL IN EUROPE OF GUARDANT360® CDX AS COMPANION DIAGNOSTIC FOR ASTRAZENECA’S ETCAMAH™ (CAMIZESTRANT) IN ADVANCED ER-POSITIVE BREAST CANCER
Source text: ID:nBwbqjLxja
Further company coverage: GH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines